N-Benzyloxycarbonyl-O-acetyl-D,L-serin | 4108-26-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-Benzyloxycarbonyl-O-acetyl-D,L-serin
• 英文别名: N-Carbobenzoxy-O-acetyl-DL-serin；O-acetyl-N-benzyloxycarbonyl-serine；O-Acetyl-N-benzyloxycarbonyl-serin；3-(Acetyloxy)-2-{[(benzyloxy)carbonyl]amino}propanoic acid；3-acetyloxy-2-(phenylmethoxycarbonylamino)propanoic acid
• CAS: 4108-26-3
• 化学式: C₁₃H₁₅NO₆
• 分子量: 281.265
• InChiKey: LILHBTZTKFFRPW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  20
• 可旋转键数：
  8
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  102
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  N-Benzyloxycarbonyl-O-acetyl-D,L-serin 在 硫酸 、 氨 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 生成 N-Carbobenzoxy-DL-serin-tert.-butylester
  参考文献：
  名称：

  The Tertiary Butyl Group as a Blocking Agent for Hydroxyl, Sulfhydryl and Amido Functions in Peptide Synthesis

  摘要：

  DOI：

  10.1021/ja00885a020
• 作为产物：
  描述：

  Cbz-DL-丝氨酸 、 乙酰氯 在 苯 作用下， 生成 N-Benzyloxycarbonyl-O-acetyl-D,L-serin
  参考文献：
  名称：

  516. O-乙酰基和O-羰基苄氧基丝氨酸的N-羧基酐

  摘要：

  DOI：

  10.1039/jr9520002735

文献信息

• NMDA Receptors Modulators and Uses Thereof
  申请人：Moskal Joseph

  公开号：US20130035292A1

  公开（公告）日：2013-02-07

  Disclosed are compounds having enhanced potency in the modulation of NMDA receptor activity. Such compounds are contemplated for use in the treatment of diseases and disorders, such as learning, cognitive activities, and analgesia, particularly in alleviating and/or reducing neuropathic pain. Orally available formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.

  本发明涉及具有增强效力的化合物，其可调节NMDA受体活性。这样的化合物可用于治疗疾病和疾病，如学习、认知活动和镇痛，特别是减轻和/或减少神经病理性疼痛。本发明还公开了口服制剂和其他药学上可接受的化合物给药形式，包括静脉给药制剂。
• NMDA RECEPTOR MODULATORS AND USES THEREOF
  申请人：Northwestern University

  公开号：US20150051262A1

  公开（公告）日：2015-02-19

  Disclosed are compounds having enhanced potency in the modulation of NMDA receptor activity. Such compounds are contemplated for use in the treatment of diseases and disorders, such as learning, cognitive activities, and analgesia, particularly in alleviating and/or reducing neuropathic pain. Orally available formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.

  本发明涉及具有增强的NMDA受体活性调节作用的化合物。这样的化合物被考虑用于治疗疾病和障碍，如学习、认知活动和镇痛，特别是在缓解和/或减轻神经病理性疼痛方面。本发明还公开了口服制剂和其他药学可接受的化合物给药形式，包括静脉注射制剂。
• NMDA Receptor Modulators and Uses Thereof
  申请人：Northwestern University

  公开号：US20150315237A1

  公开（公告）日：2015-11-05

  Disclosed are compounds having enhanced potency in the modulation of NMDA receptor activity. Such compounds are contemplated for use in the treatment of diseases and disorders, such as learning, cognitive activities, and analgesia, particularly in alleviating and/or reducing neuropathic pain. Orally available formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.

  本发明涉及具有增强的NMDA受体活性调节功效的化合物。这些化合物可用于治疗疾病和障碍，如学习、认知活动和镇痛，特别是在缓解和/或减轻神经病理性疼痛方面。本发明还揭示了口服制剂和其他药学上可接受的化合物递送形式，包括静脉注射制剂。
• Cooperative Effects of Functional Groups in Peptides. II. Elimination Reactions in Aspartyl-(O-acyl)-serine Derivatives¹
  作者：Yechiel Shalitin、Sidney A. Bernhard

  DOI：10.1021/ja00972a035

  日期：1966.10
• PHARMACEUTICAL COMBINATION OF AN ATYPICAL ANTIPSYCHOTIC AND AN NMDA MODULATOR FOR THE TREATMENT OF SCHIZOPHRENIA,BIPOLAR DISORDER, COGNITIVE IMPAIRMENT AND MAJOR DEPRESSIVE DISORDER
  申请人：Northwestern University

  公开号：EP3362080A1

  公开（公告）日：2018-08-22